A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease
A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease
Alzheimer's disease (AD) is the most common form of dementia and is characterised by a worsening of cognition, functional ability, and behaviour and mood. The objective of this study was to review the clinical and cost-effectiveness of memantine for the treatment of patients with moderately severe to severe AD. To achieve this, a systematic search and review of the clinical and cost effectiveness literature for memantine was undertaken. The literature search covered the period from the inception of MEDLINE, Cochrane Library, EMBASE and other electronic databases until July 2004. The search included randomised controlled trials (RCTs) and full economic evaluations that assessed the use of memantine in patients with moderately severe to severe AD.Two published RCTs were included in this review; in one of these trials the participants were already being treated with donepezil. The two RCTs showed benefit for patients receiving memantine compared with placebo on the outcome measures of the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia, the Clinician's Interview-Based Impression of Change Plus Caregiver Input, and the Severe Impairment Battery, and that memantine appeared to be slightly more effective in patients already receiving a stable dose of donepezil. Five cost-effectiveness studies were included in the review. Although these studies reported cost reductions and improved outcomes with memantine, the evaluations were based on a number of assumptions.In conclusion, memantine appears to be beneficial when assessed using functional and global measurements. However, the effect of memantine on cognitive scores and behaviour and mood outcomes is less clear. Cost-effectiveness is dependent upon assumptions surrounding clinical effect and context-specific cost data. [References: 29]
Activities of Daily Living Activities-of-Daily-Living Aged Alzheimer Disease Behavior Clinical Trials as Topic Cognition Cost-Benefit Analysis Dementia Disease Dopamine Agents Economics Humans medline Memantine Models,Economic Outcome Assessment (Health Care) Quality-Adjusted Life Years Research Therapeutic Use Therapy Treatment Outcome.
227-240
Kirby, J.
5cb348b3-e7cd-44f9-8382-7fa3b93a8580
Green, C.
efbb2392-25cf-4261-9fae-2b7e237b7c46
Loveman, E.
06ff1bf1-0189-4330-b22d-f5a917e9871d
Clegg, A.
838091f5-39df-4dbe-a369-675b26f2301b
Picot, J.
324d6f20-a105-49fd-9fb0-88791be84ada
Takeda, A.
f6243016-c00a-46eb-bb0d-dbbbc4dcdd6e
Payne, E.
862f8fcf-711d-4146-a723-a9109339c70a
March 2006
Kirby, J.
5cb348b3-e7cd-44f9-8382-7fa3b93a8580
Green, C.
efbb2392-25cf-4261-9fae-2b7e237b7c46
Loveman, E.
06ff1bf1-0189-4330-b22d-f5a917e9871d
Clegg, A.
838091f5-39df-4dbe-a369-675b26f2301b
Picot, J.
324d6f20-a105-49fd-9fb0-88791be84ada
Takeda, A.
f6243016-c00a-46eb-bb0d-dbbbc4dcdd6e
Payne, E.
862f8fcf-711d-4146-a723-a9109339c70a
Kirby, J., Green, C., Loveman, E., Clegg, A., Picot, J., Takeda, A. and Payne, E.
(2006)
A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.
Drugs & Aging, 23 (3), .
(doi:10.2165/00002512-200623030-00005).
Abstract
Alzheimer's disease (AD) is the most common form of dementia and is characterised by a worsening of cognition, functional ability, and behaviour and mood. The objective of this study was to review the clinical and cost-effectiveness of memantine for the treatment of patients with moderately severe to severe AD. To achieve this, a systematic search and review of the clinical and cost effectiveness literature for memantine was undertaken. The literature search covered the period from the inception of MEDLINE, Cochrane Library, EMBASE and other electronic databases until July 2004. The search included randomised controlled trials (RCTs) and full economic evaluations that assessed the use of memantine in patients with moderately severe to severe AD.Two published RCTs were included in this review; in one of these trials the participants were already being treated with donepezil. The two RCTs showed benefit for patients receiving memantine compared with placebo on the outcome measures of the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia, the Clinician's Interview-Based Impression of Change Plus Caregiver Input, and the Severe Impairment Battery, and that memantine appeared to be slightly more effective in patients already receiving a stable dose of donepezil. Five cost-effectiveness studies were included in the review. Although these studies reported cost reductions and improved outcomes with memantine, the evaluations were based on a number of assumptions.In conclusion, memantine appears to be beneficial when assessed using functional and global measurements. However, the effect of memantine on cognitive scores and behaviour and mood outcomes is less clear. Cost-effectiveness is dependent upon assumptions surrounding clinical effect and context-specific cost data. [References: 29]
This record has no associated files available for download.
More information
Published date: March 2006
Additional Information:
bek, 9102074 0 (Dopamine Agents). 19982-08-2 (Memantine) Journal Article. Research Support, Non-U.S. Gov't. Review English RefMgr field[16]: New Zealand
Keywords:
Activities of Daily Living Activities-of-Daily-Living Aged Alzheimer Disease Behavior Clinical Trials as Topic Cognition Cost-Benefit Analysis Dementia Disease Dopamine Agents Economics Humans medline Memantine Models,Economic Outcome Assessment (Health Care) Quality-Adjusted Life Years Research Therapeutic Use Therapy Treatment Outcome.
Identifiers
Local EPrints ID: 413039
URI: http://eprints.soton.ac.uk/id/eprint/413039
ISSN: 1170-229X
PURE UUID: db768f46-4968-4251-947f-4d3f26ed879c
Catalogue record
Date deposited: 14 Aug 2017 16:30
Last modified: 16 Mar 2024 03:38
Export record
Altmetrics
Contributors
Author:
J. Kirby
Author:
C. Green
Author:
A. Takeda
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
